INTRA-CELLULAR THERAPIES INC (ITCI) Stock Price, Forecast & Analysis
USA - NASDAQ:ITCI - US46116X1019 - Common Stock
ITCI Key Statistics, Chart & Performance
The current stock price of ITCI is 131.87 USD. In the past month the price increased by 0.48%. In the past year, price increased by 92.68%.
ITCI Latest News, Press Relases and Analysis
ITCI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.63 | 887.25B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.29B | ||
| MRK | MERCK & CO. INC. | 9.74 | 214.26B | ||
| PFE | PFIZER INC | 7.77 | 141.29B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.91B | ||
| ZTS | ZOETIS INC | 18.86 | 52.99B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.92 | 23.78B | ||
| VTRS | VIATRIS INC | 4.34 | 11.79B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.42 | 10.69B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.02 | 7.70B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.96B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.10B |
Related stock screener links
About ITCI
Company Profile
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 860 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Company Info
INTRA-CELLULAR THERAPIES INC
135 Route 202/206, Suite 6
Bedminster NEW JERSEY 10016 US
CEO: Sharon Mates
Employees: 610
Phone: 16464409333
INTRA-CELLULAR THERAPIES INC / ITCI FAQ
Can you describe the business of INTRA-CELLULAR THERAPIES INC?
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 860 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Can you provide the latest stock price for INTRA-CELLULAR THERAPIES INC?
The current stock price of ITCI is 131.87 USD. The price decreased by -0.04% in the last trading session.
What is the dividend status of INTRA-CELLULAR THERAPIES INC?
ITCI does not pay a dividend.
How is the ChartMill rating for INTRA-CELLULAR THERAPIES INC?
ITCI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the employee count for ITCI stock?
INTRA-CELLULAR THERAPIES INC (ITCI) currently has 610 employees.
Can you provide the market cap for INTRA-CELLULAR THERAPIES INC?
INTRA-CELLULAR THERAPIES INC (ITCI) has a market capitalization of 14.05B USD. This makes ITCI a Large Cap stock.
ITCI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ITCI. When comparing the yearly performance of all stocks, ITCI is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
ITCI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ITCI. While ITCI has a great health rating, there are worries on its profitability.
ITCI Financial Highlights
Over the last trailing twelve months ITCI reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.46% | ||
| ROE | -6.5% | ||
| Debt/Equity | 0 |
ITCI Forecast & Estimates
18 analysts have analysed ITCI and the average price target is 133.21 USD. This implies a price increase of 1.02% is expected in the next year compared to the current price of 131.87.
For the next year, analysts expect an EPS growth of 127.35% and a revenue growth 40.33% for ITCI